SPDR S&P Pharmaceuticals ETF

  • XPH

One Iron Street,
Boston , MA, 02210

Rank

Rank Universe
6 23

Summary

The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies in the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in the securities comprising t More

Webiste

Directors

Sep 12, 2023
  • Sandra G. Sponem
  • Dwight D. Churchill
  • Gunjan Chauhan
  • Carolyn M. Clancy
  • Carl G. Verboncoeur
  • James E. Ross
  • Clare S. Richer
  • Kristi L. Rowsell

Chief Compliance Officer

  • Brian Harris

Price

  • $ 44.7 ( -0.8 )
  • Feb 03, 2025
    Last Close
  • Net Assets
  • $222.6M
    Feb 27, 2024
  • 52-Week High/Low
  • $48.3 - $39.1

  • Expense Ratio
  • -

Performance

YTD

0%

3 Year

4%

5 Year

-2.8%

Best

118.12%

2000

Worst

-23.2%

2016

Company Name

Holding

State Street Global Advisors 5.69 %
Axsome Therapeutics Inc 4.27 %
Viatris Inc 4.08 %
Eli Lilly & Co 4.02 %
Zoetis Inc 3.97 %
Pfizer Inc 3.97 %
Organon & Co 3.96 %
Catalent Inc 3.96 %
Intra-Cellular Therapies Inc 3.95 %
Bristol-Myers Squibb Co 3.94 %
More 3.94 %

Documents

NAV

Annual Return

Alpha - XPH and S&P